Owen N. Witte is Director at Allogene Therapeutics, Inc. (ALLO). They have made 7 open-market trades across 2 companies since 2017, most recently 2023-06-13.
CIK 0001700969
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $270K since 2018, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALLO | SELL | 2022-08-11 | 2022-08-15 | $16.75 | $251K | -9.5% | -16.5% | -43.5% |
| ALLO | SELL | 2022-06-22 | 2022-06-23 | $11.76 | $118K | -5.0% | +11.7% | -5.4% |
| ALLO | SELL | 2021-09-09 | 2021-09-09 | $25.54 | $128K | +0.2% | -46.7% | -25.2% |
| ALLO | SELL | 2021-08-20 | 2021-08-23 | $23.39 | $351K | +8.4% | +7.0% | -23.4% |
| ALLO | SELL | 2021-06-09 | 2021-06-11 | $25.05 | $499K | -9.6% | -8.9% | -2.8% |
| ALLO | BUY | 2018-10-15 | 2018-10-17 | $18.00 | $270K | -6.7% | +13.5% | +13.3% |
| KITE | SELL | 2017-06-23 | 2017-06-26 | $100.30 | $2.5M | +4.6% | +10.1% | +77.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.